Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678368 | 0.85 | MEN1 (0.41) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6679197 | 0.84 | ALDH1A1 (0.49) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL7115636 | 0.82 | KMT2A (0.49) | KMT2AMEN1CYP3A4CYP2C9NR3C2 | |
| SCHEMBL7116631 | 0.81 | KMT2A (0.47) | KMT2AMEN1CYP3A4CYP2C9NR3C2 | |
| SCHEMBL6685134 | 0.80 | MAPT (0.49) | NR3C2ALDH1A1HTTSMN1; SMN2RXFP1 | |
| SCHEMBL6683575 | 0.79 | GAA (0.46) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6788504 | 0.76 | ALDH1A1 (0.39) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6789742 | 0.75 | LMNA (0.40) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL6682663 | 0.74 | PKM (0.47) | KMT2ACYP3A4CYP2C9ALDH1A1LMNA | |
| SCHEMBL6678378 | 0.73 | PKM (0.50) | KMT2AMEN1CYP3A4CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | KMT2A 3799/4885MEN1 3549/4885CYP3A4 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.